We have been making for quite some time for a patient capsules with Na-secobarbital. It is missing as a raw material, only available as a base. Should we consider a change in bioavailability here?
We have been making for quite some time for a patient capsules with Na-secobarbital. It is missing as a raw material, only available as a base. Should we consider a change in bioavailability here?